-
151061
Effects of erythropoietin on osteoblast in the tooth extraction socket in mice periodontitis model
Published 2022-10-01Get full text
Article -
151062
Lnc-C2orf63-4-1 Confers VSMC Homeostasis and Prevents Aortic Dissection Formation via STAT3 Interaction
Published 2021-12-01Get full text
Article -
151063
Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
Published 2024-03-01“…Noboru Yamamoto,1 Anthony Tolcher,2 Navid Hafez,3,4 Iwona Lugowska,5 Rodryg Ramlau,6 Teresa Macarulla,7,8 Junxian Geng,9 Jian Li,9 Michael Teufel,9 Angela Märten,10 Patricia LoRusso3 1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; 2NEXT Oncology, San Antonio, TX, USA; 3Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA; 4The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA; 5Early Phase Clinical Trials Unit, Maria Skłodowska Curie National Research Institute of Oncology, Warsaw, Poland; 6Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland; 7Vall d’Hebrón University Hospital, Barcelona, Spain; 8Vall d’Hebrón Institute of Oncology (VHIO), Barcelona, Spain; 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, GermanyCorrespondence: Noboru Yamamoto, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, Tel + 81-3-3542-2511 ext 7319, Email nbryamam@ncc.go.jpBackground: In patients with advanced biliary tract cancer (BTC), first-line chemotherapy plus immunotherapy has improved outcomes; however, second-line options that reflect the disease’s molecular heterogeneity are still needed. …”
Get full text
Article -
151064
Bioactive Bibenzyl Enantiomers From the Tubers of Bletilla striata
Published 2022-06-01Get full text
Article -
151065
-
151066
-
151067
Calix[n]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine
Published 2022-05-01Get full text
Article -
151068
-
151069
-
151070
Increased sinusoidal export of drug glucuronides is a compensative mechanism in liver cirrhosis of mice
Published 2023-11-01Get full text
Article -
151071
miR766-3p and miR124-3p Dictate Drug Resistance and Clinical Outcome in HNSCC
Published 2022-10-01Get full text
Article -
151072
-
151073
-
151074
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
Published 2021-06-01Get full text
Article -
151075
Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer
Published 2023-07-01Get full text
Article -
151076
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
Published 2023-03-01“…Jonathan Corren,1 David J Jackson,2,3 Thomas B Casale,4 Larry Borish,5,6 Klaus F Rabe,7,8 William W Busse,9 Jorge F Maspero,10 Daniel J Jackson,11 Nadia Daizadeh,12 Arman Altincatal,12 Amr Radwan,13 Angela Khodzhayev,13 Michel Djandji,12 Juby A Jacob-Nara,12,14 Paul J Rowe,14 Yamo Deniz13 1David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2King’s College London, London, UK; 3Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 4Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA; 5Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, VA, USA; 6Carter Immunology Center, University of Virginia Health System, Charlottesville, VA, USA; 7LungenClinic Grosshansdorf (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany; 8Christian-Albrechts University (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, Germany; 9UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 10Fundación CIDEA, Buenos Aires, Argentina; 11University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 12Sanofi, Cambridge, MA, USA; 13Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 14Sanofi, Bridgewater, NJ, USACorrespondence: Jonathan Corren, David Geffen School of Medicine at UCLA, 10780 Santa Monica Blvd., Suite 280, Los Angeles, CA, 90025, USA, Email jcorren@ucla.eduPurpose: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 (T2) inflammation in multiple diseases. …”
Get full text
Article -
151077
-
151078
Anticorrosive Effects of Essential Oils Obtained from White Wormwood and Arâr Plants
Published 2023-07-01Get full text
Article -
151079
-
151080